3-{4-oxo-5-[5-(4-sulfamoylphenyl)furan-2-ylmethylene]-2-thioxo-thiazolidin-3-yl}-propionic acid | 851304-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{4-oxo-5-[5-(4-sulfamoylphenyl)furan-2-ylmethylene]-2-thioxo-thiazolidin-3-yl}-propionic acid
• 英文别名: (E)-3-(4-oxo-5-((5-(4-sulfamoylphenyl)furan-2-yl)methylene)-2-thioxothiazolidin-3-yl)propanoic acid；3-[(5E)-4-oxo-5-[[5-(4-sulfamoylphenyl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
• CAS: 851304-23-9
• 化学式: C₁₇H₁₄N₂O₆S₃
• 分子量: 438.506
• InChiKey: GTVFZNHKGILTIR-NTEUORMPSA-N

物化性质

• 沸点：
  702.1±70.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  197
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-溴丙酸 、 4-[5-[(E)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzenesulfonamide 在 三乙胺 作用下， 生成 3-{4-oxo-5-[5-(4-sulfamoylphenyl)furan-2-ylmethylene]-2-thioxo-thiazolidin-3-yl}-propionic acid
  参考文献：
  名称：

  Methods of modulating neurotrophin-mediated activity

  摘要：

  本发明揭示了一种调节神经生长因子和脑源性神经营养因子与神经营养受体相互作用的组合物。还揭示了使用该发明的组合物的方法，包括给药方法。

  公开号：

  US20050282840A1

文献信息

• [EN] RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE RHODANINE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2004043955A1

  公开（公告）日：2004-05-27

  This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as cancers.

  这项发明描述了罗丹宁衍生物和制药组合物，可用作泛素化抑制剂。该发明的化合物和组合物可用作参与泛素化的生物体的生化途径的抑制剂。特别地，这些化合物和组合物可用于治疗细胞增殖性疾病，如癌症。
• Rhodanine derivatives and pharmaceutical compositions containing them
  申请人：Singh Rajinder

  公开号：US20060276520A1

  公开（公告）日：2006-12-07

  This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as cancers.

  本发明描述了罗丹宁衍生物和药物组合物，用于抑制泛素化。本发明的化合物和组合物可用作生物体中泛素化涉及的生物化学通路的抑制剂。特别地，这些化合物和组合物可用于治疗细胞增殖性疾病，如癌症。
• RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS
  申请人：Singh Rajinder

  公开号：US20090137644A1

  公开（公告）日：2009-05-28

  This invention describes compounds and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating diseases caused by viruses such as poxviruses and retroviruses. The invention further provides for methods of treating smallpox, Herpes virus and HIV infection in patients using the compounds and compositions of the invention.

  这项发明描述了化合物和制药组合物，可用作泛素化抑制剂。该发明的化合物和组合物可用作生物体中泛素化参与的生化途径的抑制剂。特别是，该化合物和组合物可用于治疗由病毒引起的疾病，如痘病毒和逆转录病毒。该发明还提供了使用该化合物和组合物治疗天花、疱疹病毒和HIV感染患者的方法。
• PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY
  申请人：Technische Universitat Dresden

  公开号：US20170189522A1

  公开（公告）日：2017-07-06

  The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75 NTR , which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75 NTR signalling selected from a p75 NTR antagonist or p75 NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75 NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75 NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75 NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75 NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.
• US7566732B2
  申请人：——

  公开号：US7566732B2

  公开（公告）日：2009-07-28